Results 61 to 70 of about 18,356 (247)

Medical treatment of dystonia [PDF]

, 2016
Therapeutic strategies in dystonia have evolved considerably in the past few decades. Three major treatment modalities include oral medications, botulinum toxin injections and surgical therapies, particularly deep brain stimulation.
Pichet Termsarasab, Steven J. Frucht, Thananan Thammongkolchai   +2 more
core   +2 more sources

The Spectrum of Abnormal Tongue Movements: Review of Phenomenology, Etiology, and Differential Diagnosis

Movement Disorders Clinical Practice, EarlyView.
ABSTRACT Background Classifying abnormal tongue movements is challenging due to their varied presentations and limited visibility compared to other body parts. Accurate identification of the phenomenology guides physical examination and can point to specific diagnoses.
Nathaniel Bendahan, Seyed‐Mohammad Fereshtehnejad, Christos Ganos, Emily Swinkin, Anthony E. Lang   +4 more
wiley   +1 more source

Acute dystonia in a patient with 22q11.2 deletion syndrome

Mental Illness, 2015
The 22q11.2 deletion syndrome (di George syndrome) is one of the most prevalent genetic disorders. The clinical features of the syndrome are distinct facial appearance, velopharyngeal insufficiency, conotruncal heart disease, parathyroid and immune ...
Konstantinos Kontoangelos, Antonis Maillis, Maria Maltezou, Sofia Tsiori, Charalambos C. Papageorgiou   +4 more
doaj   +1 more source

Medication-induced acute dystonic reaction: the challenge of diagnosing movement disorders in the intensive care unit [PDF]

BMJ Case Reports, 2015
A 62-year-old man presented with left middle cerebral artery stroke. 1 h postadministration of tissue plasminogen activator, he received a total of 4 mg of haloperidol for combativeness. He developed partial complex status epilepticus, requiring benzodiazepines, phenytoin, propofol and intubation.
Geneviève, Digby, Shirin, Jalini, Sean, Taylor   +2 more
openaire   +2 more sources

The differential diagnosis of Huntington's disease-like syndromes: 'red flags' for the clinician [PDF]

, 2013
A growing number of progressive heredodegenerative conditions mimic the presentation of Huntington's disease (HD). Differentiating among these HD-like syndromes is necessary when a patient with a combination of movement disorders, cognitive decline ...
Bhatia, KP, Martino, D, Stamelou, M
core  

Diagnoses behind patients with hard-to-classify tremor and normal DaT-SPECT: a clinical follow up study [PDF]

, 2014
The [(123)I]ioflupane—a dopamine transporter radioligand—SPECT (DaT-SPECT) has proven to be useful in the differential diagnosis of tremor. Here, we investigate the diagnoses behind patients with hard-to-classify tremor and normal DaT-SPECT.
Arias Carrión, Óscar, Menéndez González, Manuel, Salas Pacheco, José M., Tavares Sánchez, Francisco José, Zeidan, Nahla   +4 more
core   +1 more source

Efficacy Remaining at Time of Requested Re-Treatment for Cervical Dystonia: A Potential New Treatment Paradigm with DaxibotulinumtoxinA

Toxins
The therapeutic efficacy remaining from prior treatments with botulinum toxins (BoNTs) when cervical dystonia (CD) patients prefer to be re-treated has not been well characterized. Here, we assessed the residual therapeutic efficacy of BoNT injections at
Aaron Ellenbogen, Robert A. Hauser, Atul T. Patel, Peter McAllister, Todd M. Gross, Rashid Kazerooni, Conor J. Gallagher, David A. Hollander   +7 more
doaj   +1 more source

High motor variability in DYT1 dystonia is associated with impaired visuomotor adaptation. [PDF]

, 2018
For the healthy motor control system, an essential regulatory role is maintaining the equilibrium between keeping unwanted motor variability in check whilst allowing informative elements of motor variability.
Bhatia, KP, Edwards, MJ, Galea, JM, Rothwell, JC, Sadnicka, A, Stevenson, A   +5 more
core   +4 more sources

Dysphagia and Muscle Weakness Secondary to Botulinum Toxin Type A Treatment of Cervical Dystonia: A Drug Class Analysis of Prescribing Information

Toxins
The first-line management of cervical dystonia (CD) symptoms is intramuscular injection of botulinum toxin type A (BoNTA). However, a comparison of safety among BoNTAs is difficult because, per regulatory authorities, units of BoNTA activity are not ...
Khashayar Dashtipour, Han S. Lee, Aaron Ellenbogen, Rashid Kazerooni, Todd M. Gross, David A. Hollander, Conor J. Gallagher   +6 more
doaj   +1 more source

Botulinum Toxin Physiology in Focal Hand and Cranial Dystonia

Toxins, 2012
The safety and efficacy of botulinum toxin for the treatment of focal hand and cranial dystonias are well-established. Studies of these adult-onset focal dystonias reveal both shared features, such as the dystonic phenotype of muscle hyperactivity and ...
Barbara Illowsky Karp
doaj   +1 more source